I recently returned from a 25 year class reunion; of the 200
or so class members about 120 turned up. Of the 200 we know that at least 5 have a son with autism and at least
one has a nephew with autism. So I had
my first ever “autism lunch” discussing all those tricky issues we are left to
deal with.
What was immediately apparent was how different each child’s
“autism” was and that none of them were the autism-lite variants that are now
being so widely diagnosed in older children. or even adults . Of the six, two are non-verbal, one is institutionalized, yet one talks a lot. Three sets of parents are big ABA fans and one child did not respond to ABA.
You may be wondering about that high incidence of
autism. This was not a gathering of
science boffins or mathematicians; this was at a business school. One thing is obvious, you can correlate some autism incidence with educational level. You can connect all sorts of measures of IQ to autism, from having a math prodigy in the family, to having professors at Ivy league type Universities, particularly in Mathematics. It does appear to be true that the so-called clever genes are also associated with some types of autism.
I presume that if my science-only university organized such
events the incidence of autism would be even higher.
On the way back home we met an acquaintance
at the airport, who was telling us all about his son with Sotos Syndrome. "It is not autism", we were informed, but then I
am not quite sure what is. When you look
it up, many of the symptoms look just like autism. In fact, it is a single gene dysfunction that
leads to gigantism and various elements of autism.
This brings me to the painting above of Peter the Wild Boy;
it is not me I should point out. The
above Peter was a German boy who came to live in England in the 18th
Century; he was non-verbal and is now thought to have had Pitt Hopkins Syndrome. Like Sotos, this is another
very rare single gene disorder.
We have already come across Rett Syndrome, which for some
reason is treated as autism.
Fragile X is thought of as a syndrome where autism can be
comorbid.
Timothy Syndrome is fortunately extremely rare, but I have
already drawn on it in my own research into autism.
There are also autism related disorders involving multiple
genes.
Prader–Willi
syndrome is a rare genetic
disorder in which seven genes (or some subset thereof) on chromosome 15 (q
11–13) are deleted or unexpressed (chromosome 15q partial deletion) on the
paternal chromosome. If the maternally derived genetic material
from the same region is affected instead, the sister Angelman Syndrome is the
result.
The most frequent disorder caused
by known multiple gene overexpression is Down Syndrome. We saw in earlier post that DS is caused by
the presence of all or part of a third copy of chromosome 21. This results in over-expression of some 300
genes.
Why So Many Syndromes
Even before the days of genetic testing, these syndromes had
been identified. How could that be? Each syndrome is marked by clear physical
differences.
These physical differences where used to identify those
affected.
Within autism too, sometimes there are physical
differences. Big heads, small heads,
slim stature or heavy stature, advanced bone age or retarded bone age.
So many syndromes , but
no therapies
Many of the rare syndromes have their own foundations funding
research, mainly on the basis that if there is a known genetic dysfunction
there should be matching therapy somewhere.
As of today, there are no approved therapies for any of these
syndromes.
The Futility of Genetic
Research?
A great deal of autism research funding goes into looking for
target genes. The idea goes that once
you know which gene is the problem you can work out how to correct it. There are numerous scientific journal
dedicated to this approach.
Since no progress has been made in treating known genetic
conditions leading to “autism”, is all this research effort well directed? Some clever researchers think it is not.
All I can do is make my observations from the side lines.
What do Down Syndrome, Autism and Pitt Hopkins Syndrome all have in
common?
In at least some of those affected,
they have the identical excitatory-inhibitory imbalance of GABA, that can be
corrected by Bumetanide.
If you did whole exome genetic testing on the responders with
these three conditions you would not
find a common genetic dysfunction; and yet they respond to the same
therapy.
I am actually all for continued genetic research, but those
involved have got to understand its limitations, as well as its potential.
More on GABA
This post returns to the theme of the dysfunctional GABA
neurotransmitter because the research indicates it is present in numerous of
the above-mentioned conditions.
Table 1. Summary of GABAA signaling alterations in neurodevelopmental disorders (click for the full Table)
·
Autism
·
Fragile
X
·
Rett
Syndrome
·
Down
Syndrome
·
Neurofibromatosis type 1
·
Tourette syndrome
·
Schizophrenia
·
Tuberous sclerosis complex (TSC)
·
Prader-Willi syndrome
·
Angelman Syndrome
Based on feedback to me, we should add Pitt Hopkins Syndrome to the above list.
The GABA dysfunction is not the same in all the above
conditions, but at least in some people, Bumetanide is effective in cases of
autism, Down Syndrome and Pitt Hopkins Syndrome. I suspect that since it works in mice with
Fragile-X , it will work in at least some humans.
GABAA has already been covered in some depth in
this blog, but I am always on the lookout for more on this subject, since interventions
are highly effective. It is complicated,
but for those of you using Bumetanide, Low Dose Clonazepam, Oxytocin and some
even Diamox, the paper below will be of interest.
Regular readers will know that in autism high levels of
chloride Cl− inside the neuron have been shown to make
GABA excitatory rather than inhibitory.
This leads to neurons firing too frequently; this results in effects ranging from anxiety
to seizures and with reduced cognitive functioning. Therapies revolve around reducing chloride
levels, this can be done by restricting the flow in ,or by increasing the flow
out. The Na+/K+/Cl−
cotransporter NKCC1 imports Cl−
into the neuron. By blocking this
transporter using Bumetanide you can achieve lower Cl− within the
neuron, but with this drug you also affect NKCC2, an isoform present in the kidney,
which is why Bumetanide is a diuretic.
Some experimental drugs are being tested that block NKCC1 without
affecting NKCC2 and better cross the blood brain barrier.
The interesting new approach is to
restore Cl− balance by increasing KCC2 expression at the plasma
membrane. This means increasing the
number of transporters that carry Cl− out of the neurons.
In the Modulation of GABAergic
transmission paper there is no mention of acetazolamide (Diamox) which I suggested in my posts
could also reduce Cl−, but via the AE3
exchanger. This would explain why Diamox
can reduce seizures in some people.
The paper does mention oxytocin and it does
occur to me that babies born via Cesarean/Caesarean section will completely miss this surge of the oxytocin
hormone. This oxytocin surge is suggested to be key to the
GABA switch, which should occur soon after birth when GABA switches from
excitatory to inhibitory. In much autism
this switch never takes place.
That would suggest that perhaps all babies born via
Caesarean section should perhaps receive an artificial dose of oxytocin at
birth. This might then reduce the
incidence of GABA dysfunctions in later life, which would include autism and some epilepsy.
Indeed, children born by Caesarean section (CS) are 20% more likely to develop
autism.
Conclusions and
Relevance This study confirms previous findings that children born by CS
are approximately 20% more likely to be diagnosed as having ASD. However, the association did not persist when using sibling
controls, implying that this association is due to familial confounding by
genetic and/or environmental factors.
So as not to repeat the vaccine/autism scare, the researchers do not say that Caesarean section
leads to more autism, rather that the kinds of people who are born by Caesarean
section already had an elevated risk of autism.
This is based on analysing sibling pairs, but I do not entirely buy into
that argument. They do not want to scare
people from having a procedure that can
be life-saving for mother and baby.
If you look at it rationally, you can see that the oxytocin surge at birth is there for an
evolutionary reason. It is very easy to
recreate it with synthetic oxytocin.
Another interesting point is in the conflict of interest
statement:-
Laura Cancedda is on the Provisional
Application: US 61/919,195, 2013. Modulators of Intracellular Chloride Concentration For Treating An
Intellectual Disability
Regular readers will note that in this blog we have known for
some time that modifying GABAA leads to improved cognitive
function. I even suggested to Ben-Ari
that IQ should be measured in their autism trials for Bumetanide. IQ is much less subjective than measures of
autism.
Conclusion
My conclusion
is that while genetic testing has its place, it is more productive to look at identifying
and treating the downstream dysfunctions that are shared by many individual
genetic dysfunctions.
By focusing
on individual genes there is a big risk of just giving up, so if you have Pitt Hopkins Syndrome, like Peter the
Wild Boy, it is a single gene cause of “autism” and there is no known therapy. Well it seems that it shares downstream consequences
with many other types of autism, so it is treatable after all.
I also think more people need to consider that cognitive
dysfunction (Intellectual Disability/MR) may indeed be treatable, and
not just via GABA; so good luck to Laura Cancedda.